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Abstract
Background: Tumor cells with stem-like phenotype and properties, known as cancer stem cells (CSC), have been identified
in most solid tumors and are presumed to be responsible for driving tumor initiation, chemoresistance, relapse, or
metastasis. A subpopulation of cells with increased stem-like potential has also been identified within sarcomas. These cells
are endowed with increased tumorigenic potential, chemoresistance, expression of embryonic markers, and side
population(SP) phenotype. Leiomyosarcomas (LMS) are soft tissue sarcomas presumably arising from undifferentiated cells
of mesenchymal origin, the Mesenchymal Stem Cells (MSC). Frequent recurrence of LMS and chemoresistance of relapsed
patients may likely result from the failure to target CSC. Therefore, therapeutic cues coming from the cancer stem cell (CSC)
field may drastically improve patient outcome.
Methodology/Principal Findings: We expanded LMS stem-like cells from patient samples in vitro and examined the
possibility to counteract LMS malignancy through a stem-like cell effective approach. LMS stem-like cells were in vitro
expanded both as ‘‘tumor spheres’’ and as ‘‘monolayers’’ in Mesenchymal Stem Cell (MSC) conditions. LMS stem-like cells
displayed MSC phenotype, higher SP fraction, and increased drug-extrusion, extended proliferation potential, self-renewal,
and multiple differentiation ability. They were chemoresistant, highly tumorigenic, and faithfully reproduced the patient
tumor in mice. Such cells displayed activation of EGFR/AKT/MAPK pathways, suggesting a possibility in overcoming their
chemoresistance through EGFR blockade. IRESSA plus Vincristine treatment determined pathway inactivation, impairment
of SP phenotype, high cytotoxicity in vitro and strong antitumor activity in stem-like cell-generated patient-like xenografts,
targeting both stem-like and differentiated cells.
Conclusions/Significance: EGFR blockade combined with vincristine determines stem-like cell effective antitumor activity in
vitro and in vivo against LMS, thus providing a potential therapy for LMS patients.
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Introduction
Soft tissue sarcomas constitute a heterogeneous group of rare
tumors, accounting for 1% of adult neoplasias and 10% of
pediatric malignancies [1]. Leiomyosarcomas (LMS), representing
5 to 10% of all soft tissue sarcomas, are malignant soft tissue
tumors with smooth muscle differentiation. Similarly to other types
of sarcomas, they most probably arise from the undifferentiated
cells of mesenchymal origin, the Mesenchymal stem cells (MSC)
[1,2,3,4,5]. Patients are treated with wide surgical excision
followed by radiotherapy in most cases [2,3]. Despite this local
treatment, the rate of metastatic relapse is about 40% at the 5 year
follow up [6]. Over the last few years, adjuvant chemotherapy has
demonstrated increased survival benefit for treated patients.
However, the outcome remains poor, and patients with relapsed
disease remain largely incurable. In the past, all subtypes of soft
tissue sarcomas were merged into the same retrospective analyses,
thus reporting a global weak response to chemotherapy in clinical
trials and a median survival generally lower than 1 year. More
recently, the analysis of selected histological variants exposed to
specific histology-tailored treatments, have demonstrated a better
response rate [7,8,9,10]. These retrospective analyses and
subsequent prospective studies documented clinical benefit for
LMS patients treated with doxorubicin, gemcitabine/docetaxel
combination regimens, temozolomide and the recently introduced
biological agent trabectedin [7,11,12,13,14]. However, the clinical
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outcome in relapsed patients remains poor, calling for innovative
drugs directed against key molecular targets involved in tumor
development and progression. The AKT-mTOR pathway activa-
tion has been identified as a key event for the development of LMS
[15]. Therefore, targeting key elements of these survival pathways
may lead to more effective antitumor strategies against LMS. In
addition, even targeting deregulated oncogenic and survival
pathways might not be sufficient to achieve tumor cell death,
since other mechanisms may contribute to chemoresistance of soft
tissue sarcomas, including their marked ability to limit intracellular
accumulation of anti-neoplastic agents by active drug extrusion
[16]. Increased chemoresistance and survival, as well as elevated
membrane transporter activity, has been associated to stem-like
cells. Therefore, innovative hints for the battle against solid tumors
may emerge from cancer stem cells (CSC) research [17].
Important studies have highlighted a key role of CSC in
development, maintenance, metastasis, chemoresistance and
relapse of solid tumors, indicating these undifferentiated trans-
formed stem cells as primary targets for more effective anti-cancer
therapies [18,19,20,21,22,23,24]. CSC have been recently iden-
tified in bone sarcoma cell lines as a small subpopulation of cells
capable of forming suspended spherical, clonal colonies in
anchorage independent, serum-starved conditions, and expressing
embryonic and MSC antigens [25,26,27]. Another study identified
sarcoma initiating-cells in different types of sarcomas based on
their ability to extrude Hoechst 33342 dye, determining their Side
Population (SP) phenotype [28]. SP cells displayed high tumor-
igenic potential, while the proportion of SP cells correlated with
tumor aggressiveness, suggesting that interfering with the SP
phenotype or with other CSC properties could constitute a
strategy to counteract soft tissue sarcoma aggressiveness [28,29].
These reports highlighted the possibility to investigate the
existence and nature of CSCs in different types of soft tissue
sarcomas, paving the way for potential identifycation of innovative
therapeutic targets for these deadly cancers [29]. Here, we exploit
two different technologies to isolate and expand LMS-CSCs. The
availability of exponentially growing CSCs, allowed us to obtain in
vitro characterization of the tumorigenic population and develop
preclinical therapeutic models to investigate more effective
treatments for LMS patients.
Materials and Methods
Ethics Statement
Tumor samples were obtained in accordance with consent
procedures approved by the Internal Review Board of Depart-
ment of Surgical Sciences, Division of General Surgery, La
Sapienza University, Rome, Italy and by the International Review
Board for Research on solid tumors (Research Line 4) of Division
of Pathology, Centro di Riferimento Oncologico, Istituto Nazio-
nale Tumori, Aviano, Italy. All patients agreed to participate in
the study and signed an informed consent form.
According to the Legislative Decree 116/92 which has
implemented in Italy the European Directive 86/609/EEC on
laboratory animal protection, the research protocol ‘‘Analysis of
effectiveness and tolerability of anti-tumor therapeutic agents in
mice carrying cancer stem cell-derived tumors’’ (Principal
Investigator Dr. Adriana Eramo) has been approved by the
Service for Biotechnology and Animal Welfare of the Istituto
Superiore di Sanita` and authorized by the Italian Ministry of
Health (Decree nu 217/2010-B). The animals used in the above
mentioned research protocol have been housed and treated
according to Legislative Decree 116/92 guidelines, and animal
welfare was routinely checked by veterinarians from the Service
for Biotechnology and Animal Welfare.
Isolation and Culture of Leiomyosarcoma Stem and
Differentiated Cells
Tissue dissociation and culture of cell suspension were obtained
as previously described for tumor sphere obtainment [18,19].
Alternatively, cell growth of undifferentiated LMS cells as
adherent cultures was obtained in culture conditions used for
MSC (a-MEM medium supplemented with 20% MSC-suitable
FBS, Stem Cell Technologies). Differentiated primary cultures
were obtained as adherent monolayers following growth condi-
tions suitable for sarcoma cell lines. Cells obtained from freshly
dissociated tumors were cultivated in DMEM medium supple-
mented with 10% FBS, or alternatively tumor spheres were
dissociated and cultured under the same conditions.
Self-renewal Assay
To evaluate the fraction of self renewing cells, undifferentiated
or differentiated LMS cells or MSC were plated on 96-well plates
at a concentration of a single cell per well. Wells containing either
none or more than one cell were excluded from the analysis.
Colonies were counted after 4 weeks. For secondary sphere
formation assay, single spheres obtained from primary cloning
were dissociated in single cells, re-plated and treated as for primary
spheres.
Mesenchymal Differentiation of LMS Stem like-cells
LMS stem-like cell differentiation toward mesenchymal lineages
was obtained using hMSC differentiation bullet Kit-Osteogenic, -
Chondrogenic or –Adipogenic following the manufacturer’s
instructions (Lonza, East Rutherford, NJ, USA). The acquisition
of differentiation markers was evaluated by visible chemical/stain
reaction with Oil red O (Sigma-Aldrich, St. Louis, Mo, USA) for
adipogenic, with Alkaline Phosphatase substrate kit III (Vector
Laboratories, Burlingame, CA, USA) for osteogenic or by alcian
blue-PAS staining of differentiated cell pellet after cytoinclusion.
Flow Cytometry, SP and Drug Efflux Ability Assay
Flow cytometry antibodies used were: PE-conjugated anti
CD105 from R&D, PE-conjugated anti CD146, CD166 and
CD73, FITC-conjugated anti CD44, PE-cy5 conjugated anti c-Kit
(all from BD) and Smooth Muscle Actin (Dako). Stained cells were
analyzed with FACSCanto (BD). For SP, LMS stem-like cells and
LMS differentiated cells (16105) were incubated for 90 min with
10 mg/ml Hoechst 33342 (Molecular Probes) dye alone or with
50 mM Verapamil (Sigma), counterstained with 100 mg/ml 7AAD
to exclude non-viable cells and analyzed with a dual wavelength
analysis (blue, 424–444 nm; red, 675 nm) with excitation with
350 nM UV light (FACS LSRII, BD). For drug efflux evaluation,
intracellular doxorubicin retention assay was performed as
previously described. Briefly, 2 hours of exposure to 5 mM
doxorubicin (uptake) was followed by washing and overnight
incubation in fresh culture medium (efflux). Intracellular doxoru-
bicin-linked fluorescence was measured by flow cytometry.
Cell Cycle Analysis
Cells (16105) were washed with PBS and re-suspended 0.1%
sodium citrate, pH 7.4/0.1% Triton X100, containing 100 mg/ml
propidium iodide and 200 mg/ml RnaseA. After 2 hrs of
incubation at 4uC, samples were analyzed with FACSCanto (BD).
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Immunohistochemistry
Formalin-fixed paraffin-embedded 3 micron tissue sections were
deparaffinized in xylene and rehydrated in a graded series of
alcohol. The tissue sections were automatically stained for Smooth
Muscle Actin (Roche Diagnostics, clone 1A4), Ki-67 (Roche
Diagnostics, clone 30-9), on Benchmarker XT (Roche Diagnostics)
following the manufacturer’s directions. Immunohistochemical
stainings for pEGFR (clone 53A5, Cell signaling technology), EGF
(polyclonal, Novus Biological), myogenin, myoglobin, vimentin,
muscle specific actin HHF35 and caldesmon (all from Roche) were
performed using avidin-biotin-peroxidase complex (UltraTek
HRP, Scy Tek Laboratories). Slides were counterstained with
hematoxylin and permanently mounted.
Western Blot and Reverse Phase Phosphoproteomic
Array (RPPA)
Proteins were resolved on 4–12% polyacrylamide gels
(Invitrogen) and transferred to nitrocellulose membranes. Rabbit
polyclonal anti-Phospho-Akt (Ser473), -Phospho-S6 (Ser240/
244), -Phospho EGFR (Tyr 1068) were purchased from Cell
Signaling. Mouse monoclonal anti-PTEN was purchased from
BD, anti-Phospho-ERK (clone E-4), rabbit polyclonal anti-Bcl-2
and anti-BAX (N20) were from Santa Cruz. Mouse monoclonal
b-actin clone (A5441) was by Sigma.
RPPA was performed as previously described [30]. Briefly, for
RPPA analysis samples were lysed using T-PER (Tissue Protein
Extraction Reagent, Thermo Scientific, Waltham, MA, USA) and
diluted up to 0.5 mg/mL with Novex Tris-Glycine SDS Sample
Buffer 2X (Invitrogen Corporation, Carlsbad, CA, USA). Subse-
quently, protein lysates were spotted in a two-fold 5 point dilution
curve onto nitrocellulose-coated microscope slides via Aushon
Arrayer 2470 (Billerica, MA, USA). Then each slide underwent
incubation with a single validated primary antibody using DAKO
Autostainer Plus (DAKO Corporation, Glostrup, Denmark).
Signal amplification was performed by using DAKO CSA kit
(Catalyzed Signal Amplification, DAKO) and diamminobenzidine
was used for colorimetric detection of the primary antibody signal.
Total protein quantification was performed using Sypro Ruby
Protein Staining solution (Invitrogen) and total protein slides were
scanned using a Vidar Revolution 4200 microarray scanner (Vidar
Systems Corporation, Herndon, VA, USA). Antibody slides were
scanned using a flatbed scanner and raw images were loaded into
MicroVigene software (VigeneTech Inc., Boston, MA, USA) for
secondary antibody subtraction and normalization to total protein.
Drug Treatment and Proliferation Assay
Cells (2.56103) were seeded in 96-well plates and exposed for
72hours to: Vincristine 15 nM, Doxorubicin 100 nM, Temozolo-
mide 250 mM, Dacarbazine 5 mg/ml, Etoposide 10 mg/ml,
Gemcitabine 250 mM, Docetaxel 1 mg/ML, IRESSA 10 mM. Cell
viability was detected with Cell Titer Glo (Promega). For cell
proliferation assay cells were counted by Trypan Blue exclusion.
In vivo Leiomyosarcoma Xenografts Generation and Mice
Treatments
Cell suspensions were mixed 1:1 with growth factor reduced
Matrigel (BD) and injected subcutaneously in the flanks of four
week-old female NOD-SCID mice (Charles River). For drug
treatment, when tumors reached a mean of 0.5 cm diameter, mice
were assigned into 4 treatment groups: a) control (vehicles only); b)
IRESSA(100 mg/kg/5 days on and 2 days of/gavage); c)
Vincristine (1 mg/kg/biweekly/I.P.); d) IRESSA+Vincristine (giv-
en concurrently with the same schedules and doses as the single
drugs were given). At the end of treatments tumors were collected,
fixed in formalin and embedded in paraffin for IHC and TUNEL
assay. In each group two mice were left alive in order to check
tumor growth at the end of treatment. IHC was performed as
indicated above. Apoptotic cells were detected by TUNEL assay
(Roche) following the manufacturer’s instructions.
Results
Isolation and Phenotypic Characterization of LMS
Undifferentiated Cells
In vitro culture and expansion of sarcoma CSCs have been
obtained only from established cell lines. We investigated the
possibility to isolate and expand the small fraction of undifferen-
tiated tumor cells from a very rare form of LMS, generating long
term cultures highly enriched with these cells. Tumor cells from
enzymatically dissociated testicular LMS were cultured in
conditions that we and others have previously demonstrated to
enrich for CSC of various types as ‘‘tumor spheres’’. After
approximately 1 month of culture, surviving cells started to grow
as floating cellular clusters called ‘‘sarcospheres’’ (Figure 1A, right
bottom). In addition to the standard stem cell culture methodol-
ogy, based on the assumption that the tumorigenic cells in
sarcomas should consist in transformed undifferentiated cells of
mesenchymal origin, i.e. transformed MSC, we evaluated the
possibility to isolate these undifferentiated tumor cells in the same
culture conditions widely used for non-transformed MSCs [31,32].
Under these conditions, we obtained a monolayer of cells
resembling MSCs for morphology, after few weeks of culture
(Figure 1B, right bottom). At the same time, we cultured a fraction
of the same cells in standard conditions for cell lines in order to
obtain differentiated tumor cells. Under these conditions cells
transiently proliferated as adherent monolayers for a few weeks.
Subsequently they became quiescent, acquired the morphology of
senescent cells and ultimately died, as expected for primary
differentiated cells. In order to validate the nature of both sphere-
and adherent-cultures, we first performed their immunopheno-
typical analysis, and compared it with differentiated LMS cells
obtained under standard conditions (Figure 1 C) and with non
tumoral MSC, used as control for undifferentiated mesenchymal
cells (Figure 1D). We investigated the expression of markers
associated with mesenchymal stem and/or differentiated cells.
Both sphere-forming cells (Figure 1 A) and adherent cells (Figure 1
B) expressed high levels of CD105, CD146, CD166, CD44 and
CD90 confirming a MSC phenotype [33,34]. However, although
CD166, CD44 and CD90 were abundantly present in all three cell
culture types analyzed, as expected for these broadly expressed
mesenchymal antigens, the MSC-restricted markers CD146 and
CD105 were considerably up-regulated in both sarco-spheres
(Figure 1A) and adherent MSC-like cultures (Figure 1B) in
comparison with LMS cells obtained under standard conditions
(Figure 1C). Freshly isolated tumor cells (Figure 1E) and cells
grown in standard cultures (Figure 1C) displayed a similar
antigenic pattern. In addition, both sarcospheres and adherent
undifferentiated cells expressed high levels of the MSC marker
CD73, similarly to non tumoral MSC. This marker was also
expressed by the fresh tumor cells and cells cultured under
standard conditions. As expected, the Smooth Muscle Actin
(SMA) was expressed in all cell populations analyzed in agreement
with the smooth muscle histology of LMS, and with previous
reports showing SMA expression in non tumoral MSC (Figure 1)
[35].
These results suggest that under standard conditions, we could
obtain short term cultures of differentiated cells, while under
LMS Stem-Like Cell Targeting by EGFR Inhibition
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appropriate stem cell conditions, both experimental strategies used
(spheres and MSC-like monolayers) were suitable to select and
expand the small fraction of CD105/CD146 positive undifferen-
tiated LMS cells with stem-like phenotypes, determining their
marked enrichment within the cell cultures [34].
In vitro Cancer Stem Cell Potential of LMS
Undifferentiated Cells
We next investigated whether in vitro expanded LMS cells were
endowed with the stem cell-associated properties to extensively
proliferate, self-renew, differentiate toward multiple lineages and
extrude fluorescent dyes or drugs, as side population (SP) cells.
Both spheres and adherent cultures could be maintained in vitro
for several months, by passaging them approximately once a week
indicating that they were endowed with the CSC-associated
property of extensive proliferative capacity (Figure 2A shows the
growth rate of cells after being kept in culture for more than 20
passages). The growth rate was particularly high in the adherent
cultures, suggesting that the medium developed for MSC is
particularly suitable for their expansion (Figure 2A). In contrast,
primary cultures obtained from freshly dissociated tumor cells,
grown under standard conditions for cell lines, showed limited
proliferation potential (Figure 2A). These results suggest that while
the long term expansion of immature tumor cells is efficient under
stem cell suitable conditions, obtaining a cell line from the same
sample is far more challenging under standard conditions.
Undifferentiated LMS were highly clonogenic in both primary
and secondary limiting dilution assay, whereas differentiated LMS
cells were unable to self renew, as indicated by the absence of
colonies obtained in the same assay (Figure 2B). In addition, the
percentage of clonogenic cells was similar in undifferentiated LMS
and MSC cultures, indicating that these culture conditions resulted
in a similar enrichment both for normal and transformed
undifferentiated mesenchymal cells. Secondary sphere formation
represents the best surrogate assay to assess self-renewal capacity in
vitro. Thus, both types of undifferentiated LMS cultures were
enriched with cells endowed with self renewal ability (Figure 2B).
We next investigated whether the LMS undifferentiated cells
behaved as their putative non-tumoral counterpart, the MSC, in
terms of multiple differentiation ability. We evaluated their ability
to differentiate toward the 3 mesenchymal lineages adipogenic,
chondrogenic and osteogenic, under appropriate culture condi-
tions. Differentiation was obtained with high efficiency as
demonstrated (Figure 2C) by the relatively high fraction of cells
that stained positive for each specific differentiation marker used:
the activity of alcaline phosphatase (osteo), staining with Blue
Alcian Pas (chondro) or Oil-red-O positivity (adipo). Based on the
reported high tumor-initiating potential of SP cells isolated from
mesenchymal tumors, we next investigated whether the undiffer-
entiated LMS cultures possessed a higher fraction of cells with SP
phenotype, compared with their differentiated counterpart. In
contrast to primary cultures, undifferentiated LMS cells displayed
a higher number of SP cells (Figure 2D). The SP phenotype is a
stem cell-feature that reflects an increased activity of ABC
transporters, enhancing the ability of tumor cells to extrude drugs.
As shown in Figure 2E, fluorescent doxorubicin was massively
removed from undifferentiated LMS cells, whereas primary
differentiated cells retained the drug-related fluorescence to a
higher extent (Figure 2E).
These results suggest that undifferentiated LMS cells grown in
stem cell media display some features shared by stem cells, such as
surface markers, SP phenotype, unlimited proliferation, increased
self renewal and multipotency. Thus, fulfiling all the in vitro
requisites for potential LMS-CSC.
Tumorigenic Potential of LMS Undifferentiated Cells and
Recapitulation of Patient Tumor Histology and
Differentiation Grade
In order to investigate whether spheres and adherent undiffer-
entiated LMS cells could be considered LMS stem-like cells, we
evaluated whether they possessed stem cell properties in vivo.
Therefore, we investigated their tumorigenic potential and their
ability to recapitulate the original patient tumor in animal models.
Subcutaneous injection of undifferentiated LMS cells in NOD-
SCID mice resulted in efficient and cell number-dependent tumor
growth (Figure 3A and 3B). Both types of undifferentiated cultures
were highly tumorigenic, with tumor growth being slightly more
rapid for adherent LMS cells (Figure 3A). In contrast, the level of
tumorigenic activity of primary differentiated cells was consider-
ably lower as tumors generated from the injection of differentiated
cells grew very slowly and with low efficiency when low numbers
of cells were injected (Figure 3B and Figure S1A).
We compared the expression of the MSC markers CD146 and
CD105 in the parental and xenograft tumors. Even though these
markers were considerably upregulated in the undifferentiated
LMS cells, the resulting tumor xenografts showed a similar
frequency like the parental tumor (Figure S1B). These results
suggest that such LMS stem-like cells were able to generate a
patient tumor-like differentiated progeny in vivo. LMS cells
obtained from these primary tumors were able to rapidly and
efficiently form secondary tumors in a dose dependent manner
(Figure 3C). This demonstrates that CSCs self-renewed in vivo
maintaining their ability to generate new tumors. Secondary
tumor growth rate was lower than that of CSC-generated primary
tumors, as expected for the injection of a cell population composed
mostly by differentiated cells (those obtained from dissociation of
primary tumor).
Mice xenografts were collected and analyzed for similarity with
the original patient tumor in terms of morphology and immuno-
histochemistry. Both sphere- (Figure 3E) and adherent culture-
(Figure 3F) generated xenografts highly resembled the patient
tumor (Figure 3D), as indicated by hematoxylin and eosin staining,
expression of the LMS diagnostic marker Smooth Muscle Actin
(SMA), caldesmon, HHF35 and vimentin (Figure 3D–F and
Figure S2A). As expected, the Rabdhomyosarcoma markers
Myogenin and Myoglobin were not expressed, further demon-
strating the ability of the LMS undifferenitated cells to differentiate
in vivo into a sarcoma of the same subtype as the patient tumor
(Figure S2A). Additionally, the equal frequency of Ki67+ cells
(between 18 and 20% in all samples as evaluated by the
observation of 10 high power fields), suggests an equal growth
rate of the different tumors (Figure3D–F). Importantly, the
histology of secondary tumors and tumors generated by differen-
tiated cells shared the same features as the primary xenograft and
the patient tumor (Figure S2C). Based on these results, both sphere
Figure 1. Undifferentiated LMS cells display a Mesenchymal Stem Cell (MSC)-phenotype. Flow cytometric detection of the indicated
antigens in undifferentiated LMS cells isolated as tumors spheres (A), as adherent cells in MSC-culture conditions (B), as differentiated cells obtained
in standard culture conditions (C), in non tumoral mesenchymal stem cells (D) or in fresh tumor cells (E). Representative FACS dot plots (SSC vs FSC),
7-AAD staining and images of the corresponding cells are reported for each condition.
doi:10.1371/journal.pone.0046891.g001
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Figure 2. Undifferentiated LMS cells display stem cell potential in vitro. A) Growth curve of undifferentiated LMS cells isolated as spheres or
adherent cultures as indicated, and of differentiated tumor cells (diff) obtained under standard conditions. The values represent mean +/2 SD of
three independent experiments. Student’ s T test was used to determine p-value. * p,0,05; **p,0,01. B) Self renewing ability (percentage of
clonogenic cells) of undifferentiated (LMS spheres and LMS adherent) differentiated (LMS diff) LMS cells and MSC. Black bars represent primary assay,
grey bars are secondary assays. Mean 6 SD of 3 independent experiments is shown. C) Mesenchymal differentiation of LMS stem like-cells: (left)
Osteogenic differentiation (Alcaline Phosphatase activity), (middle) Chondrogenic differentiation (Alcian-PAS), (right) Adipogenic differentiation (Oil-
red-O). D) Flow cytometry analysis of Hoechst 33342-stained cells. The percentage of side population (SP) cells (gated) is indicated. E) Cyto£uorimetric
profile of LMS undifferentiated (stem) and differentiated (diff) cells, untreated (Control), after O/N exposure to 5 mM doxorubicin (Uptake), or after 2 h
of drug treatment followed by washing and overnight incubation in fresh medium (Ef£ux).
doi:10.1371/journal.pone.0046891.g002
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and adherent cultures of LMS stem-like cells appear highly
tumorigenic and suitable for preclinical experiments. Given that
the MSC growth conditions provided a system of more rapidly
growing cells, adherent LMS stem-like were employed for most of
the subsequent studies. Although all the in vivo experiments were
performed in the presence of matrigel, cells injected in the absence
of matrigel retained their tumorigenic ability, which was only
delayed by the absence of a supportive microenvironment for
initial growth (Figure S2B).
Chemoresistance of LMS Stem Cells
The ability to reproduce patient tumors in immunocompro-
mised animals may provide key information on the potential
efficacy of drugs or drug-combinations at the CSC level.
Therefore, we evaluated the cytotoxic activity of the currently
used antineoplastic agents on LMS stem-like cells. In order to
mimic patient regimens, LMS-CSC were exposed to gemcitabine,
vincristine, doxorubicin, temozolomide, docetaxel, etoposide, and
dacarbazine, as single agents or to the gemcitabine/docetaxel
combination at doses comparable to those reached in treated
patients before measuring cell viability. In line with the scarce
patient response and frequent patient relapse to treatments, LMS
stem-like cells resulted resistant or only slightly sensitive to most
compounds tested (Figure 4). Some drugs, such as vincristine,
gemcitabine and docetaxel displayed a considerable activity
against LMS stem-like cells, whereas temozolomide, doxorubicin
and etoposide resulted slightly effective (Figure 4A). Although
drugs were partially cytotoxic, none of the tested compounds
significantly killed off LMS stem-like cells, confirming the need of
alternative antineoplastic strategies to treat this tumor more
effectively. In parallel, the differentiated LMS cells displayed a
similar response to chemotherapy with a slightly increased
sensitivity only to some chemotherapeutic agents, as vincristine
and the docetaxel/gemcitabine combination (Figure 4A).
Figure 3. Undifferentiated LMS cells are highly tumorigenic and reproduce the human tumor in immunocompromised mice. A)
Tumor volumes of xenografts generated by injection of spheres or adherent undifferentiated LMS cells (6 weeks post-injection). Mean 6 SD of 3
independent experiments is shown. ** p,0,01. B) Tumor growth rate of undifferentiated (adherent) or differentiated (diff) LMS cells injected
subcutaneously in NOD-SCID mice at the indicated cell doses. Mean6 SD of 3 independent experiments is shown. ** p,0,01, ***p,0,001. (C) Tumor
growth rate of secondary tumors injected subcutaneously in NOD-SCID mice at the indicated cell doses. Mean6 SD of 3 independent experiments is
shown. ***p,0,001. D) Hematoxylin and eosin (H&E) or immunohistochemistry for the indicated antigens performed on patient tumor (D), tumor
generated by subcutaneous injection of LMS spheres (E) or adherent undifferentiated cells (F). The original magnification for each image is indicated.
doi:10.1371/journal.pone.0046891.g003
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Analysis of Genetic Alterations and Pathway Activation of
LMS Stem-like Cells
In order to find potentially exploitable therapeutic targets for
killing LMS stem-like cells, we investigated the activation of several
survival/oncogenic pathways by the Reverse Phase Phosphopro-
teomic Array (RPPA) evaluating the expression levels of a platform
of selected key proteins and phosphoproteins. We found a strong
activation of the EGFR and downstream pathways Akt and
MAPK (Figure 4B). These results were confirmed by immunoblot
analysis of LMS stem-like cells in comparison with control cell
lines. We found high levels of phosphorylated EGFR, Akt, Erk, S6
and low levels of PTEN (Figure 4C). Thus, increase in EGFR
phosphorylation and decreased expression of PTEN may contrib-
ute to the activation of Akt and Erk pathways, suggesting the
possibility to overcome LMS stem-like cell survival through the
inhibition of EGFR. Differentiated LMS cells displayed even
higher EGFR pathway activation than undifferentiated cells
suggesting that EGFR could represent a potential candidate for
targeting both stem and differentiated LMS cells (Figure 4D). Both
sarcospheres and adherent undifferentiated LMS cells displayed
similar levels of p-EGFR, p-Akt and p-Erk, confirming the
assumption that LMS stem-like cells obtained with the two
alternative approaches do not differ significantly (Figure 4D).
Accordingly, we investigated by DNA sequence the presence of
genomic alterations in genes that may be linked to these altered
pathways and contribute to the tumor chemoresistance. As
reported in Table S1, EGFR, Akt, PTEN, PI3K genes resulted
not mutated, suggesting different mechanisms leading to pathway
activation.
EGFR Inhibition Leads to Reduction of Akt and Erk
Pathway Activation and LMS Stem-like Cell Chemo-
sensitization in vitro
The active state of Akt and Erk pathways suggested the
possibility to abolish or reduce LMS stem-like cell chemoresistance
through targeting such survival signals. Inhibition of EGFR could
represent a promising strategy to achieve concomitant down-
regulation of both downstream signaling pathways possibly leading
to LMS stem-like cell killing, growth inhibition or chemosensitiza-
tion. Therefore, we investigated LMS stem-like cell response to the
EGFR inhibitor IRESSA (Gefitinib) used as single agent or in
combination with chemotherapy. When used as single agent,
IRESSA reduced cell growth in the absence of cytotoxicity, as
determined by cell inspection, which revealed negligible amounts
of dead cells both in control or IRESSA-treated samples (Figure
S3A and data not shown). The combined use of IRESSA and
chemotherapeutic drugs resulted in additive anti-tumor effect,
with the highest cell death rate obtained in combination with
vincristine, both on LMS stem and differentiated cells (Figure 5A,
5B and Figure S2B). Cell cycle analysis showed that such
combination further increased the G2/M cell fraction (Figure
Figure 4. LMS stem-like cells are chemoresistant and display
high activation of Akt and Erk pathways. A) Cell viability (% vs
control, measured by cell titer glo luminescence) of undifferentiated
and differentiated LMS cells exposed for 3 days to the indicated drugs.
Mean 6 SD of 3 independent experiments is shown. ** p,0,01. B)
Reverse Phase Phosphoproteomic Array (RPPA) of LMS CSC. Standard-
ized levels of expression or phosphorylation of the indicated proteins
are reported. Standardized values were calculated for each antibody by
subtracting the mean and dividing by the standard deviation of the
sample series. Color scale limits from red to green include values
spanning from $1,5 to #21,5 standard deviations. C) Immunoblot
analysis for the indicated proteins in LMS stem-like or control (U251,
U87MG, HeLa) cells. D) Immunoblot analysis for the indicated proteins
in LMS-stem like (adherent cultures or spheres) or differentiated (diff)
cells.
doi:10.1371/journal.pone.0046891.g004
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S2C), confirming that treatment with IRESSA potentiates the
activity of vincristine. Cell death occurred mainly through
apoptosis as suggested by morphological features and annexin V
binding of treated cells (Figure S2B and Figure 5B). Reduced
phosphorylation levels of EGFR, Akt and Erk in vincristine/
IRESSA-treated cells indicated the inhibition of the whole
pathway downstream EGFR (Figure 5C). Furthermore, the
combined treatment determined a strong reduction in the anti-
apoptotic factor Bcl-2 levels, confirming that EGFR inhibition
potentiates vincristine effects also in terms of Bcl-2 down-
modulation (Figure 5C) [36]. In contrast, the levels of the anti-
apoptotic protein BAX did not vary with treatment, indicating
that the observed Bcl-2 decrease is a specific effect of treatment.
The considerable in vitro cytotoxic activity of vincristine in
combination with IRESSA may not be entirely explained by the
inhibition of survival pathways. The ability of LMS stem-like cells
to extrude cytotoxic drugs may contribute to their relative
chemoresistance. Given that IRESSA has been shown to inhibit
membrane pump activity and favor drug retention within tumors
[37,38], we investigated whether a similar effect could be obtained
in LMS stem-like cells, ultimately contributing to their death. The
analysis of Hoechst 33342 retention showed that IRESSA
exposure determined a marked reduction of the SP fraction
within the stem-like cell population (Figure 5D left), in parallel
with a prolonged accumulation of doxorubicin (Figure 5D right).
These results suggest that IRESSA enhances the cytotoxic activity
of chemotherapeutic agents by both targeting survival pathways
downstream EGFR and increasing drug retention.
IRESSA/Vincristine Treatment Results in Strong Anti-
tumor Activity in Patient Tumor Phospho-copies
Generated by LMS Stem-like Cells
To rule out the possibility that the EGFR activation observed in
LMS stem-like cells could result from culture-induced modifica-
tions, we investigated the activation state of the EGFR pathway in
the original patient tumor. In the absence of EGFR mutations in
tumor cells (see Table S1), we hypothesized that receptor
stimulation might depend on the production of high EGF levels
in the tumor microenvironment. The immunohistochemical
analysis showed the presence of a significant amount of EGF in
the parental LMS, together with diffuse phosphorylation of EGFR
(Figure 6A). Of note, a similar pattern of EGF and p-EGFR
expression was observed in LMS stem-like cell-based tumor
xenografts (Figure 6A), confirming that this experimental model
may provide a suitable tool for preclinical testing of EGFR
inhibition.
NOD-SCID mice bearing subcutaneous LMS stem-like cell-
generated tumors were treated with Vincristine, IRESSA, or their
combination. Similarly to in vitro results, treatment with IRESSA
reduced tumor growth, whereas vincristine displayed more striking
antitumor activity, particularly in combination with IRESSA
(Figure 6 B), as shown also by the macroscopic appearance of
excised tumors and tumor weights at the end of treatment (Image
in Figure 6B and results not shown). At the end of treatment most
tumors were collected and analyzed for in vivo EGFR inhibition
and apoptosis induction. The immunohistochemistry analysis
showed reduced levels of pEGFR in treated samples when
compared to controls (6C top panels), indicating that the IRESSA
levels reached in vivo were sufficient to achieve EGFR inhibition
and confirming that the antitumor effect of IRESSA was mediated
by inhibition of EGFR. In addition, TUNEL assay revealed a
consistent fraction of apoptotic cells in vincristine and, to a higher
extent, in double treated-tumors, while control and IRESSA
treated tumors did not show any sign of apoptotic cell death
(Figure 6C bottom panels).
In order to evaluate whether the single or combined treatments
were able to affect the tumorigenic cell population in vivo, we
monitored the tumor size after treatment withdrawal. Tumors
were monitored for 10 days with the aim of investigating the ability
of the single or combined treatments to abolish or delay tumor re-
growth. We observed that after therapy cessation, tumors from
vincristine-treated mice started to re-grow, whereas those subject-
ed to combined treatment continued to decrease in size and
recurred only after several weeks (Figure 6D and data not shown).
This effect was not due to the different size of treated and
untreated tumors, since we obtained similar results when we
compared the growth rate of treated tumors with controls of
similar volumes (Figure 6D). Finally, in order to investigate
whether EGF/EGFR pathway activation was a common signature
in LMS, we analyzed a panel of 10 LMS patient-derived
specimens. All samples analyzed revealed high or moderate
expression of EGF and p-EGFR levels (Figure S4A). The
expression was diffuse in all cells of the tissue although the
intensity varied in different samples, having always higher levels
than in normal samples (Figure S4B). These results indicated that
the EGF/EGFR pathway is frequently activated in LMS.
Discussion
LMS patients often relapse following surgical and radiation
treatment. Although some patients respond to the current second-
line chemotherapeutic regimens, the prognosis remain particularly
poor.
Many reports suggest that CSC have a pivotal role in tumor
chemoresistance and relapse. The ability to expand in vitro
leiomyosarcoma stem-like cells represent a powerful tool to obtain
their comprehensive characterization, which may represent the
first step toward the development of effective treatments.
Here, we report for the first time the expansion of leiomyosar-
coma initiating cells and investigated the mechanisms underlying
their weak response to most of the current treatments as well as the
possibility to increase the antitumor effect of standard chemother-
apy by concurrent inhibition of the survival pathways activated in
the LMS stem-like cells.
Immature LMS cells could be obtained by standard serum-free
culture conditions that allow selection and expansion of immature
tumor cells as ‘‘spheres’’, as we previously showed for CSC of
various solid tumors [18,19,21]. Additionally, based on the
assumption that LMS-CSC may be considered as transformed
MSC, we were able to efficiently expand the LMS-CSC in culture
conditions widely used for non transformed MSC of various
origin, thus identifying an additional method for obtaining stem-
like cell-enriched cultures from mesenchymal tumors. Alternative-
ly, another possibility might be that, rather than the expansion of
undifferentiated cells, the stem cell suitable culture conditions,
different from standard culture conditions, might influence the
antigenic pattern of cultured cells toward a MCS- like phenotype.
However, we found that both types of stem cell-suitable cultures,
although completely different, generated cultures with similar
antigenic pattern, suggesting the possibility of a function-based
selection of cells rather than phenotype remodeling.
In vitro expanded LMS stem-like cells were endowed with stem-
like cell potential in vitro and high tumorigenic potential coupled
with the ability to generate primary and secondary patient-like
tumors in immunodeficient mice, indicating that such in vitro
expanded LMS stem-like cells were able to recapitulate the
tumorigenic process by proliferating in vivo while both self-
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Figure 5. IRESSA treatment reduces LMS stem-like cell growth rate and sensitizes them to chemotherapy. A) Effect of IRESSA on LMS cell
chemo-sensitivity. (Left) Stem-like cells were exposed to IRESSA and the indicated compounds and cell viability was evaluated after 72 hours by Cell
Titer Glo assay (Promega). (Right) Cell viability of undifferentiated (stem) or differentiated (diff) LMS cells exposed to IRESSA/vincristine combination
for 72 hours. Mean 6 SD of 3 independent experiments is shown. ** p,0,01. B) Flow cytometric analysis for Annexin V of LMS stem-like cells
untreated (control) or treated as indicated. C) Immunoblot for the indicated proteins or phosphoproteins of LMS stem-like cells left untreated or
treated as indicated. D) Effect of IRESSA on SP and drug efflux ability. (Left) SP analysis of control or IRESSA-treated LMS stem-like cells. (Right)
Cyto£uorimetric profiles of control or IRESSA treated LMS stem-like cells after exposure to doxorubicin (Uptake), or after drug treatment followed by
removal and overnight incubation in drug-free medium (Ef£ux).
doi:10.1371/journal.pone.0046891.g005
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renewing and producing a progeny of differentiated cells that
constitute the major cellular population in the tumor. In
comparison to differentiated cells, stem-like cells displayed
increased tumorigenicity not only in terms of reduced latency for
tumor growth but also in terms of tumor formation efficiency. In
particular, low numbers of differentiated cells (104) displayed a
highly reduced ability to generate tumors even after long periods
of observation while stem-like cells displayed about 100% efficency
when the same number of cells were injected.
Of note, the same experimental strategies proved to be effective
in the in vitro long term expansion of undifferentiated cells from
other sarcomas (results not shown). Such in vitro expanded LMS
stem-like cells displayed the surface antigen expression expected
for undifferentiated tumor cells of mesenchymal origin.
In vitro expanded LMS stem-like cells contained a significant
fraction of cells with SP phenotype which showed a slightly
increased tumorigenic activity in comparison to the whole
population of undifferentiated cells (Figure S5).
Long term expansion of LMS stem-like cells allowed their
extensive investigation, including the evaluation of their chemo-
sensitivity. Exposure of LMS- stem-like cells to anti-neoplastic
agents currently used in the clinical practice or in clinical trials
resulted in a modest cytotoxicity. Concerning chemosensitivity,
although both stem and differentiated LMS cells resulted quite
resistant to most treatments, some drugs (in particular vincristine
and the combination docetaxel/gemcitabine) displayed higher
cytotoxicity against differentiated cells. In addition, it is important
to mention that, even if chemoresistance is not limited to CSCs,
targeting this tumorigenic population appears to be required to
obtain long-term antitumor effect. Thus, even a similar degree of
chemoresistance observed in our experimental conditions in the
two types of cells may be more relevant when associated to CSC
than to differentiated cells, the latter characterized by limited life
span.
In the absence of genetic alterations in the Akt, PI3K, PTEN
and EGFR genes (Table S1), we investigated the activation status
of key survival pathways possibly contributing to chemoresistance.
EGFR and key proteins belonging to the downstream PI3/AKT
and MAPK/ERK pathways were considerably activated in LMS
stem like cells, while the treatment with IRESSA resulted in
inhibition of the EGFR, AKT and ERK pathway, with
consequent sensitization to several chemotherapeutic agents.
We found that EGFR inhibition by IRESSA determined a
marked reduction of the drug efflux activity and of the SP fraction
within the LMS stem-like cells. Thus, the strong chemo-
sensitization effect of IRESSA may rely on its ability to affect
both survival pathway signaling and active drug extrusion.
LMS stem-like cells were able to generate patient-like tumors
also in terms of EGFR activation, a prerequisite for preclinical
testing of antitumor compounds targeting this receptor. IRESSA
plus Vincristine treatments were highly cytotoxic and were found
to strongly counteract tumor growth. However, vincristine-treated
tumors immediately started to re-grow after treatment cessation.
Their growth rate even increased compared to non-pretreated
tumors, while double treatment caused a long delay before the
tumor started to slowly re-grow. A plausible interpretation of these
results may be that the relative number of tumorigenic cells could
be enriched by vincristine treatment and not by combined
therapy. In other words vincristine most likely affected viability
of differentiated tumor cells sparing LMS-stem-like cells, while the
combination treatment was effective against both stem-like and
differentiated cells. This is in line with recent data from our group
showing that in different solid tumors chemotherapy spares
quiescent rather than proliferating cancer stem-like cells [39,40].
However, another interpretation might be that vincristine could
determine the selection of cells with increased proliferative
potential. What is not questionable is that tumors treated with
chemotherapy were growing more actively after interrupting
treatment while IRESSA-chemo treated tumors did not regrow for
a longer period of time. Therefore, it is reasonable to hypothesize
that similarly to mice such CSC-effective therapeutic strategy
might determine a longer progression free survival in patients and
a slow progression of relapsing tumors.
Previous studies showed that EGFR targeting combined with
chemotherapy displayed marked antitumor activity against some
sarcoma cell lines both in vitro and in vivo [41,42]. Our results are in
agreement with these studies and further point toward this
treatment direction demonstrating for the first time the efficacy
of EGFR targeting in chemosensitization of LMS stem-like cells.
Furthermore, finding that IRESSA, besides EGFR pathway
inactivation, strongly inhibits the stem cell-associated active drug
extrusion, may explain the efficacy of the combination therapy
against the tumorigenic cells. The detection of EGFR phosphor-
ylation in all the LMS analyzed suggests that EGFR targeting
agents may constitute a valuable therapeutic tool for those LMS
patients lacking driving molecular alteration downstream of
EGFR. High levels of EGF within the tumor may possibly be
responsible for receptor activation and suggest the possibility to
obtain anticancer activity against LMS through the direct
inhibition of EGF. However, it remains to be elucidated whether
EGF is secreted by cancer or stroma cells.
In conclusion, our study proposed a potential therapeutic
strategy that might be effective for LMS patients with EGFR
pathway activation. The efficacy of this therapeutic strategy most
likely relies on its multitarget activity, as it resulted both in a
simultaneous inactivation of multiple oncogenic signals, and in the
inhibition of CSC-linked properties leading to cytotoxicity against
the more aggressive tumorigenic cell population. Additional
functional studies will extend our analysis to larger numbers of
LMS patient tumors, aiming to increase reliability of results and
provide potential alternative treatments to lengthen survival of
relapsed LMS patients unresponsive to current clinical regimens.
Supporting Information
Figure S1 A) Tumorigenicity of stem and differentated LMS
cells. Percentage of tumor positive mice after injection of low
numbers of stem-like or differentiated LMS cells. 5 mice were
injected with 104 cells and tumor formation evaluated after 4
months. B) In vivo differentiation of LMS stem-like cells. Flow cytometry
Figure 6. IRESSA/Vincristine treatment results in strong stem-like cell-effective anti-tumor activity in patient tumor phospho-
copies generated by LMS-stem-like cells. A) LMS stem-like cells derived xenografts display high levels of EGF and p-EGFR similarly to the patient
tumor. A) EGF and p-EGFR immunohistochemistry in patient tumor specimens and in LMS-CSC derived xenografts. B) Tumor growth curves and
tumor pictures of LMS-CSC derived xenografts in control, IRESSA-, Vincristine- or IRESSA+Vincristine- treated mice. Mean 6 SD of 3 independent
experiments is shown. **p,0,01. C) p-EGFR immunohistochemistry and TUNEL assay of control or treated xenografts. The percentage of Tunel
positive cells is indicated for each condition. D) Tumor growth rate of control or pre-treated tumors after treatment interruption. Pre-treated tumors
were monitored after 10 days and tumor growth is indicated as ratio of tumor volume at day10 vs day0.The white bar represents growth rate of
additional control tumors comparable to treated tumors in size. Mean 6 SD of 3 independent experiments is shown. ** p,0,01.
doi:10.1371/journal.pone.0046891.g006
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analysis for CD105 and CD146 expression in parental tumor,
sarcospheres (S), adherent culture (A) or differentiated LMS cells
obtained from freshly dissociated xenografts generated by sarco-
sphere or adherent culture cell injection. The percentage of
positive cells is represented by the different histograms corre-
sponding to the cell populations or tumor types as indicated.
(TIF)
Figure S2 A) Immunohistochemistry for the indicated antigens
performed on patient tumor (left), tumor generated by subcuta-
neous injection of LMS spheres (middle) or adherent undifferen-
tiated cells (right). B) Tumor growth rate of undifferentiated LMS
cells (adherent cultures) injected subcutaneously in NOD-SCID
mice with or without Matrigel as indicated. The values represent
mean +/2 SD of three independent experiments. Student’ s T test
was used to determine p-value. ***p,0,001. C) Hematoxylin and
eosin (H&E) or immunohistochemistry for the indicated antigens
performed on secondary tumors or tumors generated by
differentiated LMS cells, as indicated.
(TIF)
Figure S3 A) Effect of IRESSA on LMS stem-like cell
proliferation. LMS stem like cells were plated and left untreated
or exposed to IRESSA for the indicated time points. Cell growth is
indicated as percentage of treated cell versus control cell numbers
ateach time. B) Morphologycal appearance of LMS stem-like cells
untreated (control) or treated 3 days as indicated. C) Cell cycle
distribution of the same cells as in B after 2 days drug esposure.
(TIF)
Figure S4 EGF/EGFR pathway is generally activated in
leiomyosarcomas. A) p-EGFR and EGF immunohistochemistry
in 3 out of 10 representative patient-derived LMS specimens. B)
Table showing the EGF and pEGFR expression in 10 LMS patient-
derived specimens and in 5 non tumoral tissue specimen
(Myometrium). Values 1 to 4 indicating the percentage of positive
cells with 0= negative, 1,10%; 2= 10–25%; 3= 25–50%,
4,50% and letters A to C indicating the intensity of expression
(A=weak,; B=moderate; C=high intensity).
(TIF)
Figure S5 A) Cytofluorimetric cell sorting of side population (SP)
cells (right panel). B) Tumor growth rate of xenografts generated
by subcutaneous injection of sorted SP cells and unsorted
undifferentiated LMS cells (adherent cultures). The values
represent mean +/2 SD of three independent experiments.
Student’ s T test was used to determine p-value. **p,0,01.
(TIF)
Table S1 Genetic pattern of LMS stem-like cells. The specific
primers used for amplification of the listed genes are reported.
PCR products were analyzed and compared with the correspond-
ing Genebank sequences of each gene for the presence of tumor-
associated alterations. The status of DNA is indicated as wt when
similarity among PCR product and genebank sequence was 100%.
(XLS)
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